North American Prodromal Synucleinopathy (NAPS) Consortium

Overview

About this study

The purpose of this study is to establish a registry of RBD patients, develop quantitative biological and functional measures of synucleinopathy burden, and establish a formal process to evaluate candidate neuroprotective agents.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Undergone an overnight polysomnogram that was used to diagnose REM Sleep Behavior Disorder.
18 years of age or older.
Capable of providing informed consent using the current IRB approved consent document.

Exclusion Criteria:

Known diagnosis of PD, dementia of any type, or MSA,
RBD associated with narcolepsy or suspected due to another neurological etiology (i.e. non-idiopathic RBD),
For Lumbar puncture only: Anticoagulant medication or bleeding disorder,
For Lumbar puncture only: Prior lumbar surgery or procedure that precludes LP.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Bradley Boeve, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Boeve, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials